JPH05503071A - Odor blocking and stabilizing composition to treat keratinous tissue, skin conditions and promote wound healing - Google Patents

Abstract

(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

[Detailed description of the invention] Odor blocking and stabilization to treat keratin tissue, skin conditions and promote wound healing Composition Summary of the invention The present invention utilizes a thin film-forming protein component, a reducing agent, and optionally at least one substituent. Relating to a novel composition comprising: a reactive zinc salt, a cationic polymer and /or cationic or nonionic surfactants. In addition, oxidizing agents and/or Optionally contains antioxidants. The compositions of the present invention promote wound healing, reduce abrasions and Dislocations, gum bombs, oral sores and wounds, corneal ulcers and epidermal abrasions. Cures skin abnormalities including eruptions and seborrhea, dandruff, psoriasis and other skin conditions It is particularly effective in treating rash-like indications, scleroderma and acne scars. Composition of the invention It also reduces scarring associated with severe conditions of sitting or injury, and reduces exposure to sunlight. It is used to improve wrinkles in the skin caused by exposure to sunlight or aging. present invention Treatment methods include eczematous dermatitis, chronic dermatitis, equine granulomas, and decubitus ulcers. in mammals, including ulcers and canine cutaneous granulomas (“Lick J granulomas”). It is effective as a veterinary tool to reduce debilitation associated with certain skin diseases.

The compositions of the invention may also be applied to mammalian and animal hooves and hair, such as human hair and nails. Cosmetic substances that improve the keratin tissues of the stratum corneum and improve their strength and appearance. It is also useful. In addition, these compositions can be used to treat the hair and nails of mammals including humans. Also useful for promoting growth and stabilizing hair loss.

a film-forming protein composition, a reducing agent and optionally a sufficient amount of at least one of the following components: minutes, zinc salts, cationic polymers and cationic or nonionic surfactants, compositions of the invention, and also optionally comprising an oxidizing agent and/or an antioxidant composition. Things such as damage, purulent dermatosis, seborrhea, psoriasis, zapping, various eruptions, itching, hard skin, Corns, burns, eczematous dermatitis, chronic dermatitis, bedsores, various skin eruptions, non-specific Dermatitis and granuloma vulgaris in horses (granuloma vulgaris) and skin granuloma in dogs (Lick granuloma) ) was found to exhibit surprising activity in treating certain veterinary conditions, including . The compositions of the present invention strengthen and improve the appearance of hair, nails, skin and other skin. It can be used to stimulate the growth of latin substances and stabilize hair loss.

The composition of the present invention prevents ingrown hairs and promotes healing of ingrown hairs.

When the composition of the present invention is a reducing agent, it contains a thiol-containing film-forming protein composition. Demonstrates the substantial absence of odors normally associated with storage of materials. The composition of the present invention The combination of reducing agent and film-forming proteins substantially reduces the odor associated with reducing agents containing The effect of the combination will be maintained. Partially thiol-containing reducing agents and film-forming proteins By substantially reducing the malodor associated with storage of compositions containing The composition smells good, making it tempting to use the composition. The composition is therapeutic When used, patient compliance increases.

The essential components of the compositions of the present invention are reducing agents and film-forming proteins, zinc salts, carbon at least one selected from cationic polymers and cationic or nonionic surfactants. Optionally, one type of substance is also included. In addition, the composition of the present invention may contain an oxidizing agent and/or Or it may also contain an antioxidant. For example, water, bases, acids, buffers, emulsifiers are surface active It also contains many other ingredients such as thickeners, thickeners, preservatives, colorants and fragrances. obtain.

Background of the invention U.S. Pat. No. 4,438,102 promotes normal dermal and epidermal tissue growth. Compositions useful for promoting soft keratin (keratin) tissue of the epidermal layer are described. have been described as useful in promoting wound healing. The composition of said patent is , thioglycolic acid, ammonium hydroxide, glycerin, citric acid, hydrogen peroxide , gelatin, lower alkanols and solvents such as acetone or diethyl ether. It is stated that the medium is contained in a predetermined percentage. Some examples of wound healing illustrate the It's listed in the details.

U.S. Pat. No. 4,195,095 describes fatty cysts, dandruff, scleroderma, and Certain formulations containing thioglycolic acid for the treatment of other skin conditions, including acne scars The use of is described. A typical composition is thioglycolic acid, hexa Chlorophene, sodium hydroxide, water and fillers or gelling polymers and preservatives. Contains other ingredients including active ingredients.

US Pat. A method for adhering a peptide product to human hair is described. This method is , carrying out a permanent reduction step in the presence of said peptide product, followed by a second step. , brings about the effect by performing oxidation.

U.S. Patent No. 4,711.780 describes ascorbic acid, zinc salt, sulfur amino acid and optionally a mucopolysaccharide and/or a polysaccharide for treating the surface epithelium. Drugs are listed. The compositions of this patent can be used to treat many infections and infections, including healing wounds. It has been described as useful in treating conditions.

British Patent No. 2.160.419 describes contacting hair, skin or nails with a reducing agent. Process: rinsing the treated tissue with water; hydrating the rinsed tissue with aqueous keratin protein and finally contacting the tissue with a neutralizing composition containing an oxidizing agent. Treatment and improvement of keratin tissue conditions, consisting of only three steps: The method is described.

In the absence of the sulfur-stabilizing component of the present invention, a thin film-forming protein (preferably an activated A composition containing a thiol-containing film-forming protein) and a reducing agent is highly effective. However, some compositions tend to develop a pungent odor that is very unpleasant. be. In some cases, such compositions may be damaged due to this malodor. will be used less frequently.

Therefore, it is possible to use at least one film-forming protein in combination with a reducing agent to provide long-term i.e. substance with a malodor or unpleasant odor even after storage for at least about 3 months Treats keratinous tissue, such as hair, skin and nails, that has no evidence of or does not occur Makes the tissue stronger, sensually and visually more comfortable, inverted, and e.g. For example, injuries, gingival bombardment, oral wounds and lesions, corneal ulcers and abrasions, eczematous skin. Dermatitis, chronic dermatitis, bedsores, seborrhea, psoriasis, purulent dermatosis, dandruff, itching, wrinkles , allergic skin reactions, various skin eruptions, abnormal skin conditions including acne, and horse meat. Treats certain veterinary conditions including blister and canine cutaneous granulomas (“rick” granulomas). One object of the present invention is to provide novel compositions and/or methods for treating It is.

Another object of the present invention is to improve keratin tissue, inverted skin conditions and the above mentioned skin conditions. The activated thiol-containing protein composition does not exhibit any bad odor even after storage for a long period of time, and the activated thiol-containing protein composition acts as an oxidizing agent. treated with a composition that allows said composition to remain active even when containing It is an object of the present invention to provide non-malodorous, shelf-stable therapeutic compositions and methods.

Another object of the invention is to treat chronic veterinary skin conditions that do not respond to conventional treatments. , for example, granulomas (granulomas) in horses and cutaneous granulomas (“rick” granulomas) in dogs. The objective of the present invention is to provide a non-maldorable, shelf-stable composition for the treatment of cancer. The present invention Another purpose of the invention is to prepare the tissue with at least one of an activating protein and a reducing agent and, optionally, Seed components, reactive zinc salts, cationic polymers, cationic and nonionic surfaces keratin tissue, including skin and nails, by exposure to a surfactant selected from active agents Tones hair, increases its strength, appearance and feel, stimulates hair growth and reduces wrinkles. It is an object of the present invention to provide new compositions and methods for improving appearance. This initiative It has been shown to be surprisingly effective in treating the skin conditions listed above.

These and other objects of the invention will be readily apparent from the following description of the invention. Can be done.

Detailed description of the invention The therapeutic compositions and methods of the present invention treat keratin and damage, gingival sores, oral wounds and lesions, corneal ulcers and epidermal desquamation, seborrhea, psoriasis, dandruff, allergic skin reactions , acne, itching, hard skin, corns, burns, abrasions, wrinkles, various skin eruptions, non-specific related conditions, including dermatitis and eczematous dermatitis, chronic dermatitis, and equine granulomatosis ( Certain veterinary conditions include canine cutaneous granulomas ("rick" granulomas) and canine cutaneous granulomas ("rick" granulomas). It is useful for treating conditions. In addition, the compositions and methods of the present invention also the strength, condition and appearance of hair, skin and nails, including broken hair, nails and hooves; used to improve hair and nail growth, and prevent hair loss.

In the practice of the invention, an activated protein, a compatible reducing agent, and optionally at least One of the following ingredients, a reactive zinc salt, a cationic polymer, and a cationic and a surfactant selected from the group consisting of nonionic surfactants. contact with the affected area of keratinous tissue in one of the conditions described above. Furthermore, optionally , oxidants and/or antioxidants may be included in the formulations of the present invention. The therapeutic composition of the present invention and The method is used to treat non-healing skin conditions, especially granuloma granulomas in horses and skin conditions in dogs. Shows activity against sexual granulomas (“rick” granulomas). Certain compositions of the invention include non- stable compositions without exhibiting malodor or a substantial reduction in activity; It is a surprising result that it is active in a wide range of indications without having to do so. In addition, the main The composition of the present invention includes at least one of the following substances, a reactive zinc salt, a cationic polymer, - and by compositions containing no cationic or nonionic surfactants. does not show any substantial "puckering" of the packaging.

Compositions useful in the treatment methods of the invention have a pH of about 3 to about 10, preferably Compositions having a pH of about 4 to about 9 are included. The pH of the composition used is Depending on the particular application of the composition, the above pH range may include a pH of 7.6 (physiological pH). changes within the range. The compositions of the present invention include a composition reducing agent, a film-forming protein, preferably a is an activated film-forming protein, optionally one or more reactive zinc salts, and a cationic polymer. and a surfactant selected from cationic and nonionic surfactants and others. Contains less essential components of. Oxidizing agents and/or non-oxidizing agents may also be included in the formulation. It can be rare.

Preferably, the film-forming protein is a hydrate. Hydrated proteins are found in some skin conditions. It is advantageous for conditions and wounds, especially burns. Because hydrated proteins bring additional moisture to the skin This is because it can be expected to give The protein in the composition of the present invention may be human or animal. reacts with the keratin of the skin and forms chemical bonds, thereby moistening the hydrated proteins adhere to the skin. Accordingly, the composition may be used to treat human or animal skin and to A medium that chemically binds activated proteins to the skin to moisturize and moisturize dry skin. It is useful for delivering other drugs to dehydrated skin. Composition of the invention Proteins in substances react with the hard keratin of human and animal hair, nails and skin, Forms chemical bonds, thereby reducing hair splitting, increasing hair thickness, and nails Increases the firmness of nails, reduces nail fraying and delamination, and delivers moist, hydrated proteins to the skin. Achieve what you give. The compositions of the invention also serve as topical pharmaceutical carriers and excipients. Function.

The amount of film-forming protein that binds to the skin is a function of the type of film-forming protein used. can vary greatly. Proteins that do not contain sufficient cysteine thiol groups are , to the same extent or for the same duration as proteins containing sufficient cysteine thiol groups. During this period, it does not bind to the keratin substrate.

Furthermore, such proteins are intercalated between the proteins as is the case with keratin. It does not become part of the natural skin. In the case of activated proteins, keratin tissue The percentage of activated protein that binds to the activated protein depends on the concentration of reducing agent in the composition and the activated protein. Varies with the number of activated thiol or mercapto groups in the plasma and keratin tissue . The time of contact of the reducing agent with the keratinous tissue is also important. Keratin tissue returns The longer the contact with the base agent, the more covalent bond formation of protein-keratin tissue is observed. be included.

The compositions of the present invention are preferably used at ambient temperature, i.e. between about 20°C and 35°C. However, higher temperatures are recommended, especially for treating hair and nails of animals, including humans. may also be used. When treating wounds, especially burns, it is clear that the treatment It is performed at a lower temperature to avoid worsening the wound condition. using heat as a treatment Treatment at high temperatures is recommended if it is considered advantageous to . Keratin tissue (hair and nails) is treated for about 5 minutes to about 6 hours. . Keratinous tissue can be removed acutely or chronically with or without bandaging as needed. treated. In certain embodiments, combinations useful in carrying out the therapeutic methods of the invention The compositions are formulated to have sustained or controlled release of the polymer and are active. Create formulations that can provide long-term drug delivery.

The reaction was performed by contacting the composition of the invention with the keratinous substrate to be treated and This is accomplished by drying the tissue. Contact time can be varied arbitrarily.

In addition to the film-forming protein, the compositions of the invention contain at least one reducing agent, preferably contains a pharmaceutically compatible reducing agent. The reducing agent preferably reduces the keratin substrate. , in an amount sufficient to promote covalent binding of the film-forming protein.

Free thiol groups can be generated from cysteine disulfide bonds. Although any reducing agent may be used in embodiments of the present invention, the preferred reducing agent is a pharmaceutical containing thiol-containing reducing agents that are compatible with each other.

In addition to the film-forming protein and the reducing agent, the composition preferably contains reactive zinc salts, surface active agents selected from ionic polymers and cationic and nonionic surfactants; Contains at least one substance selected from sex agents. Reactive zinc salts are used Reactive zinc salts surprisingly retain their broad range of activity and odor It has an effective concentration to produce a stable product that is blocked.

As used herein, a reactive zinc salt is present in the compositions of the present invention. is any zinc salt that can be dissolved up to about 0.05% by weight. Used in the present invention Preferred reactive zinc salts that can be used in water or in formulating the compositions of the invention are Zinc salts include any zinc salt that can be dissolved in other carriers. Many zinc salts of this invention Preferred zinc salts are readily soluble in water, either singly or in combination. Including those that can be dissolved. Other reactive zinc salts used in the present invention include Or slightly soluble in other carriers, but not soluble when incorporated into the compositions of the present invention. The solvability includes those that are greatly increased. Such reactive zinc salts are inter alia zinc oxide (2n　O) included. Generally, the amount of reactive zinc salt used is about 0.05 wt. % to the solubility limit of the zinc salt in water or other suitable carrier used. good Preferably, at least about 0.19% by weight of reactive zinc salt is used. The present invention A particularly preferred combination of zinc salts used in Zinc + ulloca + bola + e, (trade name) phenyl sulfone Zinc acid)].

The amount of reactive zinc salt included in the compositions of the invention is generally about 0.05% by weight of the composition. % to about 4% by weight, but the effect of the particular salt chosen and on the composition of the invention. The addition of cationic polymers and/or surfactants allows one skilled in the art to It will be appreciated that varying amounts of reactive zinc salts may also be used. Those skilled in the art may also The amount of reactive zinc salt used will depend on the type of zinc salt selected and the amounts of other ingredients; It is recognized that this also depends on the amount of thiol-containing compounds present in the compositions of the invention, among other things. Will.

The compositions of the invention also include at least one cationic polymer, alone or reactive. It may be included in combination with zinc salts and/or surfactants. Characteristics of cationic polymers Although the alternative structure is somewhat important to the overall efficiency of the cationic polymer, , to determine the efficiency of the cationic polymers of the invention in stabilizing the compositions of the invention. It's just one of several factors. Zinc salts and cationic polymers or cationic Surfactants and nonionic surfactants are combined with thiol-containing reducing agents and/or proteins. Complexing and stabilizing these components from disintegration into malodorous by-products can also be considered.

Typical cationic polymers include nitrogen, phosphorus, and sulfur cationic groups or It is a mixture of thione groups. Cations containing nitrogen and especially quaternary ammonium groups Particularly preferred are polymers with a 100% carbon content.

The cationic polymer of the present invention is water-soluble and contains quaternary ammonium groups. is preferred. Such polymers include nitrogen-containing cellulose ethers, quaternary nitrogen-containing Polysaccharides, cellulose ethers and dialkyl diallylammonium halides Graft copolymer of polymer, vinylpyrrolidone and quarter (qua+e rnized) copolymer of dialkylaminoalkyl methacrylate, acrylic Copolymer of lylamide and quarter dialkylamino diallyl methacrylate - and other polyquaternium polymers.

The cationic polymer is contained in a thiol-containing composition, e.g., the composition of the present invention. an amount effective to substantially reduce malodor associated with storage of reducing agent and protein; used. Generally, the cationic polymer used in the present invention is from about 0.01% to about 20%, preferably about 0.025% by weight of % to about 20% by weight, most preferably about 0.1% to about 5% by weight.

As mentioned above, cationic polymers alone or with reactive zinc salts and/or surface active It can be used in combination with sex agents. The composition contains reactive zinc salts and/or zinc salts. When formulated with cationic polymers in the presence of lolidone-containing surfactants , the amount of cationic polymer is generally within the above weight range, but depending on the chosen reaction. can be reduced to accommodate zinc salts and/or surfactants.

The compositions of the invention may also contain at least one surfactant selected from cationic and nonionic surfactants. Both may contain one surfactant.

There are a number of cationic amine-containing surfactants contemplated for use in the present invention. Among them, benzalkonium bromide, benzethonium chloride, benzyl Hexadecyldimethylammonium chloride and cetyltrimethylammonium Phenyl and alkylammonium surfactants, including bromide, oxyethyl acetate ammonium phosphates, ethoxylalkyl amines and alkylimidacillins oxyethyl-substituted ammonium surfactants. 1/4 alkyria Quaternary amine-containing surface active material containing amines and 1/4 ethoxylalkyl amines Agents are clearly preferred. In compositions expressly contemplated by the present invention, other Cationic surfactants are also used.

Compositions of the invention may also contain certain at least one nonionic surfactant. . Nonionic surfactants useful in the present invention include surfactants that are complexed with mercaptides. Contains surfactant. Particularly preferred nonionic surfactants for use include, for example: Contains nonionic surfactants with cationic properties.

Certain compositions of the invention preferably include at least one pyrrolidone-containing surfactant. contains. As used herein, "pyrrolidone-containing surfactants" The term includes a pyrrolidone ring in which a hydrophobic group is attached at the nitrogen position of the pyrrolidone ring. , the hydrophobic group together with the pyrrolidone ring confers surfactant-like properties. many hydrophobic Although a preferred hydrophobic group is an n-ol group attached to the nitrogen of the pyrrolidone ring, ctyl, dodecyl and coco and tallow alkyl groups, most preferably n-octyl It is le. In the case of coco and tallow alkyl groups, these groups are It is expressed by variously changing the alkyl substituents derived from -.

In certain aspects of the invention, chelating agents, such as ethylenediaminetetraacetic acid (AD T A) or one of its chemical analogues is added to the composition in the presence of a reactive zinc salt. In addition, it increases odor reduction ability. . Such compositions are cationic as described above. optionally contains a cationic polymer and/or a cationic or nonionic surfactant. . When EDTA is used in the compositions of the present invention, it is generally about 0.0% of the composition. 05 to about 20% by weight, preferably about 02 to 0.9% by weight, most preferably about 0.35 to [1.7% by weight.

In addition to the above ingredients, the compositions of the present invention contain an oxidizing agent, an antioxidant, or an oxidizing agent and an antioxidant. Mixtures of oxidizing agents can be included. In addition, zinc salts may be added to the composition of the present invention. , containing cationic polymers, nonionic or cationic surfactants, or without containing acids, bases, buffers, emulsifiers or other surfactants, thickeners, preservatives, etc. Other ingredients may also include at least one of the following: fillers, fillers, organic solvents, colorants, and fragrances. Can be added. so as to avoid interaction with the active ingredients of the compositions of the invention Those skilled in the art will recognize that the selection of additive materials will be made.

In some embodiments of the invention, the antioxidant used allows the reaction to be accelerated by heat. be done. In this method, by removing antioxidants, Oxidation that promotes covalent disulfide formation by oxygen can be promoted. The present invention In some embodiments, after the volatile antioxidant has evaporated from the formulation, a non-volatile antioxidant that promotes oxidation is added. Use an oxidizing agent.

Generally, the compositions of the present invention contain from about 0.1% to about 25% by weight of a film-forming protein; Preferably, the activated protein component contains from about 1.0% to about 15% by weight of a compatible reducing agent. Base materials, preferably reactive zinc salts, cationic polymers and cationic and non- At least one substance selected from ionic surfactants, an oxidizing agent, and an antioxidant agents, water, acids, bases, buffers, emulsifiers or surfactants, thickeners, preservatives, organic solvents , chelating agents, film-forming polymers, colorants and fragrances. Contains one ingredient.

Preferred compositions used in the method of the invention include thiol-containing proteins and increase the production of free mercaptide or thiol groups in the protein tissue, The free thiol in the keratin tissue and the free thiol in the keratin tissue interact to form disulfide Formulated to maximize the probability of forming covalent bonds. using antioxidants or Including an oxidizing agent in the same formulation without using a second oxidizing solution helps promote covalent disulfide formation without

Besides covalent disulfide bond formation, many other factors, including the film-forming properties of the protein, The mechanism responsible for the increased activity exhibited by the therapeutic methods of the invention. bound by theory On the other hand, non-thiol-containing proteins such as gelatin or collagen can be used. The film-forming properties of the protein are most responsible for the increased activity in compositions with It is a factor.

The present invention can be applied to gels, creams, lotions, sprays or liquids with various clays. A composition formulated as

Detailed description of the invention The present invention comprises a membrane-forming protein, preferably an activated protein, a reducing agent and optionally , Reactive Zinc Salts, Cationic Polymers and Cationic and Pyrrolidone Containing Tables The present invention relates to a composition containing at least one component selected from surfactants. Other, Oxidizing agents, antioxidants, water, bases, acids, buffers, emulsifiers or surfactants, thickeners, preservatives. The present invention contains at least one component selected from natural materials, organic solvents, colorants, and fragrances. may be included in the composition.

The protein may be any membrane-forming protein. As used herein Film-forming proteins are molecules that form a thin film on a keratin substrate after being deposited. is a protein. In these compositions, the film-forming protein is deposited on the keratin matrix. used in an effective amount to form a thin film. Thin film formation used in the present invention The protein has a sufficient number of cysteines to be able to bind covalently to the keratin substrate, for example. Also included are proteins that do not contain functional thiol groups. Does not contain enough cysteine The proteins that form a thin film include collagen and gelatin, among others.

The film-forming protein comprises about 0.1 to about 25.0% by weight of the composition, preferably in some proportion. from about 1.0 to about 15.0% by weight for compounds, and from about 6 to about 10% by weight for other applications. It consists of

The thin film-forming protein used in the composition used in the present invention is compatible with many proteins. More exemplified. Preferred proteins include sufficient cysteine, i.e. hair, skin and covalently bonded to the keratinous tissue of the nail for a durable and permanent bond to the keratinous tissue. at least about 1 per 200 amino acids in the peptide chain to form Cystine amino acid (approximately at least 0.5% by weight cysteine, preferably or at least about 1.0% by weight cysteine and most preferably at least about 1.0% by weight cysteine. It contains about 5% by weight of cysteine. A persistent bond is a protein that But the keratin tissue is easily washed away and normal hair is removed without being rubbed off or rubbed off. It means that the hair and nails will remain unchanged.

Many typical film-forming proteins used in the present invention include gelatin, collagen, Contains mucin, salmin (mouth 1ml) and sturin. preferable Proteins include keratin, dietary proteins such as casein, alpha- and beta-lactoa rubumin, seed proteins such as especially soybean protein, flaxseed protein, cottonseed protein, Corn protein and peanut protein, hemoglobin, insulin, myo syn, zein, ovalbumin, trypsin, chymotrypsin, chymotrypsino -gen, elastase, thrombin, plasminogen, fibrinogen/fluor fibulin, lysozyme, papain, serum albumin, isolated from cartilage, bone and skin thermocoagulable mucoproteins, gamma-globulin blood proteins and, among others, Many blood factor proteins, including factor 1, factor X, factor 1 Xa, and factor Xa, Contains white matter. Naturally, proteins containing many cysteine residues have a keratin complex. It is preferred because it forms the most covalent bonds with the fabric, resulting in the greatest durability. present invention The most preferred film-forming proteins used in the treatment of keratin substrates are contains sufficient cysteine to covalently bond to.

Particularly preferred proteins for use in the present invention include a high proportion by weight of cysteine. Containing proteins such as ribonuclease T1, human serum albumin and γ-glucose Includes Roblin. Particularly preferred proteins for use in the present invention are those Due to the exceptionally high cysteine content (about 12 to about 17% cysteine by weight) of And because it is found in the substrate that is improved is keratin. treat a wound In compositions used to Used in combination with fibrinogen/fibrin or modified fibrinogen.

Other compositions used to treat wounds include fibrinogen/fibrin or contains a single modified fibrinogen.

The activation protein used in the present invention, i.e., the one covalently bonded to the keratin substrate. Proteins with sufficient cysteine content to contain free thiosulfate at a pH of about 9.0 or higher activated in the presence of a reducing agent for a sufficient period of time to form a group. this time is generally about 5 minutes to about 1 hour. Activation times longer than 1 hour indicate that the protein Although such time also slightly increases the amount of activated thiol groups in as it results in protein hydrolysis resulting in shorter, less advantageous peptide units. I don't like it very much.

Many globular proteins contain hydrophobic or other internal packs of the protein structure. et) contains cysteine residues.

To activate these proteins and expose cysteine groups to keratin tissue, modification is necessary. Activating cysteine residues of sexual proteins are placed closest to cysteine residues of keratin tissue. It is advantageous to denature and activate the protein to promote covalent binding. It is.

Addition of components other than the reducing agent at a pH higher than about 9.0 may cause cystinic content in proteins. adversely affects the rate at which disulfide bonds are converted to cysteine mercaptide groups. In order to give Preferably, it is activated simultaneously. This reduces the overall activity of the protein. . However, less preferred is to promote covalent bonding to keratin tissue. The cysteine content of the protein must be sufficient to activate enough cysteine residues. If the protein is at a pH lower than 9.0, and even lower, such as about 4.0, After formulation, activated proteins can be generated by simply exposing to a reducing agent at pH. It is possible.

The activated protein is preferably keratin, but the activated protein promotes binding to activated keratin tissue. All proteins containing sufficient cysteine content to promote intended for use. Preferred proteins have a high content of cysteine (generally 10 % by weight, often as high as 15-17% by weight of protein). Keratins obtained by hydrolysis of skin, feathers, wool, and hair.

A particularly preferred keratin is manufactured by Croda Chemicals International [(Cr oda Chemical+ International), Cheshire, UK Kerasol [(Ke1a+ol) is a trade name of Ko. In the present invention, The molecular weight of the protein used is preferably about 5,000 to 500,000 daltons. 120,000 to No. 000 Daltons is most preferred.

Reducing agents useful in the compositions of the invention include sulfides and dithiothreitols. (dithiojhuijol),) lithiohexitol, glutathione, cysteine, mercaptoethanol, thioglycerol, thioalkanoic acid (lh ioalkanoic zcid) and mercaptocarboxylic acid analogues, e.g. Thiols including lucatosuccinic acid, thiolactic acid and their pharmaceutically acceptable salts compositions containing thioglycolic acid, particularly thioglycolic acid and salts of thioglycolic acids. and compositions containing olefins. The preferred reducing agent for activating proteins is triglyceride. Serol, cysteine, thiolactic acid and thioglycolic acid and their pharmaceutical uses Acceptable salt. A particularly preferred reducing agent for use in the present invention is thioglycerol. salts of rolls and thioglycolic acids, especially ammonium thioglycolate . The reducing agent that activates the protein is the pharmaceutically acceptable reducing agent used in the final formulation of the invention. It is preferable to use the same reducing agent as that of compatibility (cozpa+1ble). protein Pharmaceutically highly incompatible reducing agents for activation are less preferred and The reducing agent must be removed from the activated protein before the protein is activated. Can make use more difficult.

The compositions used in the methods of the invention include a pharmaceutically compatible reducing agent at about 0% of the formulation. ．． Contains in an amount of 1 to about 15% by weight. Preferred compositions are from about 0.5 to about 1 Contains 0% by weight, most preferably greater than about 1% by weight of a pharmaceutically compatible reducing agent. do. The amount of pharmaceutically compatible reducing agent will depend on the therapeutic or aesthetic use for which the composition is intended. The amount varies depending on the intended use, but is generally about 0.1 to about 10% by weight. pharmaceutically compatible Reducing agents reduce cystinyl disulfide bonds in keratin tissue, A substance that generates free thiol or mercaptide groups and is biologically and/or Compatible with pharmaceutical systems, especially human skin and nails and/or animal skin and hooves. Ru. Pharmaceutically compatible reducing agents contemplated for use in the present invention include mercapto Ethanol, dithiothreitol, thioglycerol, thiolactic acid, glutathione , cysteine and thioglycolic acid and their salts. particularly preferred The reducing agent is ammonium thioglycolate.

The composition of the present invention comprises a reactive zinc salt, a cationic polymer and a cationic surface active compound. The composition further comprises at least one component selected from surfactants and nonionic surfactants.

Generally, the reactive zinc salt is used in an amount effective to stabilize the composition and eliminate malodors. Prevents the formation of by-products. Generally, reactive zinc salts range from about 0.05 to approximately Amounts up to the solubility limit of the zinc salt in water or other suitable carrier are used.

The amount of zinc salt used may be as low as 0.19% by weight, although it may include small amounts such as about 0.05% by weight. An amount greater than % is preferred. Preferred zinc salts used in compositions of the invention For example, zinc acetate, zinc ammonium chloride, zinc bromide, zinc butyrate, salts zinc chloride, zinc chloride, zinc fluoroborate, zinc formate, formamine sulfoxylate Rudehyde zinc (rinc Iormalde17de + ulfox71ate ), zinc iodate, zinc lactate, zinc nitrate, zinc sulfophosphate (phenylsulfonate) (zinc acid) and zinc sulfate. Low solubility zinc salts include zinc caproate, Zinc carbonate, zinc fluoride, zinc iodide, zinc laurate, zinc oxalate, zinc oxide, zinc Zinc sulfate, zinc tartrate, zinc hydride, zinc dithiocarbamate cyanide (e.g. dimethyl), zinc phosphate, potassium zinc chromate and zinc chromate tetroxide. It will be done. Particularly preferred zinc salts include zinc oxide and Zinc phenylsulfonate [zincsulloca+bolNe (trade name), Universal Preservach Em, Inc., Prutsklin, New York, USA] is used. .

The compositions of the invention also include at least one cationic polymer, alone or preferably. preferably in combination with reactive zinc salts and/or cationic or nonionic surfactants. Can be used together. In fact, the compositions of the present invention can be stabilized and freed from malodorous gases and other by-products. All cationic polymers that prevent product formation are contemplated for use in the present invention.

Such cationic polymers include synthetic, semi-synthetic and natural cationic polymers. selected from. The cationic polymer of the present invention is a polysaccharide containing a cationic group. such as, in particular, polycellulose polymers, condensation polymers, polyamides, polyoxygenates, etc. Sialkylene, polyalkyleneimine, polyacrylamide, polymethacrylate Mido, polyacrylate, polymethacrylate, polyvinylpyrrolidone, diary Homopolymer of ethylenically unsaturated compounds, including rudialkyl ammonium halides polymers and copolymers, grafts or copolymers of such materials.

The cationic polymer of the present invention is water-soluble and contains a quaternary ammonium group. preferable. Typical preferred polymers include quaternary nitrogen-containing cellulose ethers, e.g. For example, Ame+chol Corporation [(Ame+chol Carp,), USA] , New Chassis], JR-30M (trade name), JR-1 25 (trade name) and JR-400 (trade name) 30M, quaternary nitrogen-containing polysaccharide, e.g. For example, Quatrisoft [(Q aa+risoN) Trade Name Copolymer, Cellulose Ether and Dialkyl Diary Graft copolymers with ammonium halide, such as national starch ( Self-at [Cs1quu (New Chassis, USA) available from Trade name) 1 polymer, homopolymer of dialkyldiallylammonium halide and copolymers, available for example from Carbon Corporation (USA), Merquaj (trade name) copolymer, vinylpyrrolidone and 4 Copolymers of dialkylaminoalkyl methacrylate, such as GAF Gaff, available from Linden, New Chassis, USA. Fatt [Ga+qua+ (trade name) copolymer, acrylamide and a quarter Copolymers of dialkylamino dialkyl methacrylates, such as Hercule Incorporated [()le+cules, Inc,), USA, Retin (trade name) polymer and its From other poly quaternary polymers (po17qua+ernium polymer) To be elected.

The cationic polymer is a thiol-containing composition, e.g. Effective in substantially reducing odors associated with storage of raw materials and certain proteins used in large quantities. Generally, the cationic polymer will be at least about 0.01% by weight. up to about 20%, preferably from about 0.025% to about 20% by weight of the composition. , most preferably in an amount of from about 0.1% to about 5% by weight. on the skin Some cationic polymers can cause irritation when placed in close proximity There is. Those skilled in the art will be able to determine the amount of cationic polymer used in the compositions of the invention. and adjust the type.

The cationic polymer may be used alone or preferably with a reactive zinc salt and/or a cationic polymer. Or they can be used in combination with nonionic surfactants. The composition contains reactive zinc cationic polymers in the presence of salts and/or cationic or non-ionic surfactants. The amount of cationic polymer is generally within the above range. However, it can be reduced in conjunction with zinc salts and/or surfactants.

The compositions of the invention may also contain at least one selected from cationic and nonionic surfactants. Both may also contain a surfactant. Generally, surfactants are added to the compositions of the invention. It also stabilizes and prevents the formation of malodorous by-products. Therefore, mercaptide cationic properties that tend to complex and stabilize without reducing the activity of and nonionic surfactants are contemplated for use in the present invention.

All cationic surfactants that complex and stabilize mercaptides are included in the present invention. Although amines, and particularly quaternary amines, are contemplated for use in the present invention, Preferably. Generally, the surfactant will be at least about 0.0% of the composition of the invention. 05% to about 15% by weight of the composition. Preferably, the surfactant is It comprises about 0.05% to about 5% by weight of the composition of the present invention.

Cationic amine-containing surfactants contemplated for use in the present invention include, among others: Benzalkonium bromide, benzethonium chloride, benzylhexadecyldimethy Fes containing ammonium chloride and cetyltrimethylammonium bromide Nyl and alkylammonium surfactants, oxyethylammonium phosphate, Ethoxylated alkylamines, such as Henkel Corporation [Pennsylvania] The surfactant Dehyquat, available from Amble, Al. [Deh7quat (trade name)] and Mona Industry Inc. (Monalndus, Inc.), New Chassis, Oxyethyl containing alkyl imidacillin available from West Patterson Sonco Includes substituted ammonium surfactants.

1/4 alkylamine and 1/4 ethoxylated alkylamine, Monai Industries Incorporated [(Mona Industries, ll Monarch available from IC, )-, West Patterson Co., New Chassis. Quaternary amine-containing surfaces containing at [Monzquat (trade name) surfactant] Active agents are clearly preferred. Its use in compositions contemplated by the present invention Other cationic surfactants are also clearly preferred.

Compositions of the invention may also contain at least one nonionic surfactant. Book Nonionic surfactants useful in the invention include surface complexes with mercaptides. Contains an activator. Particularly preferred non-ionic compounds for use in the compositions of the invention Surfactants may, for example, have cationic properties, i.e. complexed with mercaptides, Certain resonance forms stabilize the compositions of the invention from producing malodorous by-products. Contains nonionic surfactants that have the property of existing as cations in the It will be done. Preferred nonionic surfactants for use in the present invention include alkanols. Ruamide surfactant, EIDery Corp. , ), Mauldin, South Carolina, USA] Amide 6560 (trade name), ethoxylated alkanol amides, such as ethoxylated taloamine (ethox71ajcd taloa mine), Emely Corporation [(Eme+7 Corp,), Tr7mean (trade name) available from Ko, Carolina Includes surfactants, pyrrolidone-containing surfactants. In addition to the above, for example, Seteth (se+e+h) and stearless (stea+eth) alcohol. Fatty alcohol nonionic surfactants are also included in the compositions of the present invention.

Most preferably, the composition of the invention has a hydrophobic group attached to the nitrogen of the pyrrolidone ring. contains at least one pyrrolidone-containing surfactant. pyrrolidone ring Several hydrophobic groups on nitrogen may be used; preferred hydrophobic groups include GAF Corp. Surfactants available from Ration (Linden, New Chassis, USA) LP-100 (trade name), LP-300 (trade name), LP-800 (trade name) ) and n-oct bonded to the nitrogen of the pyrrolidone ring in LP-940 (trade name). Tinope dodecyl and coco and tallow alkyl groups, most preferably n-oc Includes chill. Generally, the compositions of the present invention contain about 0.05 to about 5% by weight of pyrochloride. Contains a lydone-containing surfactant.

Reactive zinc salts, cationic polymers and/or cationic and nonionic surface activities The sexing agents, alone or in combination, are used in amounts effective to stabilize the compositions of the invention. I can stay. By stabilizing the compositions of the present invention, the compositions will be free from perceptible malodors. , precipitation, and “wrinkles” in the container caused by the reaction of the mixture with the gas present in the container. I don't.

In certain aspects of the invention, ethylenediaminetetraacetic acid (EDTA), e.g. Laenstein Incorporated [(Loven+tein, Inc.) Hampen, available from Brooklyn Co., New York, USA. ene) 100 (trade name), disodium, tetrazolium and EDTA zinc or chemical analogs thereof are added to the compositions of the invention in the presence of a reactive zinc salt. . Such compositions optionally include cationic polymers and and/or pyrrolidone-containing surfactants.

When EDTA is used in the compositions of the present invention, it generally comprises about 0.0% of the composition. 05 to about 2.0% by weight, preferably about 02 to about 09% by weight and most preferably It contains about 0.35 to 0.7% by weight.

The compositions used in the invention may additionally contain an effective amount of an oxidizing agent, generally 0.01 to 40% by weight of oxidizing agent. In preferred compositions, from about 0.01 to Contains about 1.5% by weight oxidizing agent, most preferably about 0.5 to 10% by weight. Contains oxidizing agent. The oxidant removes the shared disulfide between the activated protein and the keratin tissue. It is included in the composition of the present invention to promote the formation of compound bonds. typical oxidizing agent Hydrogen peroxide (which may or may not be stabilized, for example with urea) ammonium sulfate peroxide, urea peroxide, pyrophosphorus Acid peroxide, carbonate peroxide, acetyl peroxide, benzoyl peroxide, In particular, alkali metal perborates, including sodium perborate, sodium bromate and carbon Alkali metal bromates, sodium iodate and potassium iodate and its salts containing. In embodiments that do not include antioxidants, hydrogen peroxide is preferred. It is a good oxidizing agent. In embodiments that include hydrogen peroxide, the amount of hydrogen peroxide depends on the composition. Preferably, from about 0.01 to about 1.5% by weight of the product, and from about 0.05 to about 1.5% by weight. Most preferably, it is 0% by weight. If an oxidizing agent other than hydrogen peroxide is used, Compared to hydrogen peroxide, which has a high oxidation equivalent per unit weight, a high weight proportion is usually used. It will be done.

Of course, many therapeutic and cosmetic compositions and methods do not require the inclusion of oxidizing agents; , it is often advantageous to include an oxidizing agent. However, in some compositions The oxidizing agent promotes the polymerization of keratin molecules in situ, resulting in thinning of thiol-containing proteins. Promote favorable conditions to promote film forming properties.

In place of adding an oxidizing agent to the compositions of the present invention, or from about 0.01 to An antioxidant may be included in addition to the oxidizing agent in an amount of about 2.0% by weight. Contains antioxidants In the composition, the antioxidant is used to promote storage stability of the formulation. Contains.

Typical antioxidants include alpha-tocopherol, hydroxyquinone, and unifer. roll, tocopherol alcorbate, lecithin, chlorophyll, alcolpi Lupalmitate, linseed oil, tongac oil, US patent Others such as the steam distilled extract of rosemary disclosed in No. 4.450.097. Natural antioxidants, thiazoline carboxylates, dihydroxyphosphates, methyl gallate , propyl gallate, alkylaryl and diarylamines.

Certain chelating agents, such as EDTA, may be used to enhance the antioxidant effectiveness of the above substances. It can be used for Also, as mentioned above, EDTA can be used in formulations containing reactive zinc salts. It has been found to be advantageous to add it to products. The chelating agent absorbs oxygen in situ. can chelate all dissolved metals that may be responsible for the generation of In general, The rating agent is about 0.05% to about 2.0% by weight of the formulation, preferably about 0.2% to about 2.0% by weight of the formulation. 0.9% by weight, and most preferably from about 0.35 to about 0.7% by weight of the composition. be.

In a preferred embodiment of the invention, no oxidizing agent is included in the formulation used. 0.0% in the formulation. It contains about 2.0% of antioxidants. oxidation If no agent is added, the antioxidant will dissolve in atmospheric oxygen or solution during storage. The composition of the present invention is used to prevent proteins or reducing agents from being inactivated by oxygen. contained in the product. Oxidizing agents promote oxidation of free thiols or mercaptides However, in the composition used for covalent disulfide bonding, the oxidizing agent is from about 0.01% to about 40% by weight of the compound, and from about 0.01% to about 4.0% by weight of the antioxidant. It consists of 0% by weight.

As in other compositions of the invention, compositions containing an antioxidant and optionally an oxidizing agent Additionally, acids, bases, buffers, milk, etc., as described in other embodiments of the invention. thickeners, chelating agents, film-forming polymers, preservatives, organic May include solvents, colorants and fragrances.

The selection of additives includes film-forming proteins, reducing agents and, in some cases, reactive zinc salts, For the activity of cationic polymers, pyrrolidone-containing surfactants, oxidants or antioxidants. It will be appreciated by those skilled in the art that efforts are made to avoid influencing interactions.

In order to promote the thin film-forming effect of the protein used in the composition of the present invention, It is often preferable to add film-forming polymers to the compositions of the invention. . Among the many thin film-forming polymers, the preferred thin film-forming polymer used in the present invention is Polypyrrolidone, such as PVP K2O [GAF Charlotte [( ChxrloNe), North Carolina, Carbomer (czrbome+) , for example, Carbapol 94G [(Carbzpol 94G) trademark name Unacarbapol (trade name) polymers, polyacrylates, gums, e.g. methyl Cellulose, Hydroxymethylcellulose, Carboxymethylcellulose, Pro Includes pyl cellulose and hydroxypropyl cellulose.

Typically acids and bases are added to adjust the pH of the formulation to desired levels. be done. Examples of preferred acids include organic acids such as acetic acid, citric acid, among others. acid and tartaric acid, and -hydrogen or dihydrogen phosphoric acid (di-h7d+ogenphos Inorganic phosphoric acids including their salts, such as those of phxte). inorganic phosphoric acid Salts may also be included as buffering agents in the formulation. Examples of preferred bases include organic amines, e.g. monoethanolamine, triethanolamine, trimethyl Examples include amines and triethylamine.

The most preferred bases include ammonium hydroxide.

Buffers, such as the inorganic phosphates mentioned above, and other buffers, such as acetic acid and citric acid. A salt of an organic acid such as Contains an amount effective to. The amount of buffering agent is preferably no more than about 15% by weight of the formulation. and most preferably less than about 0.75% by weight. Formulation pH determines stability and to maintain the activity of certain components in the compound, especially the activated protein and a compatible reducing agent. This is a factor that Therefore, buffers maintain pH at a relatively constant level over time. included in the formulation to maintain

Certain additives are used to impart homogeneity to the formulation and to promote solubility of the formulation. A solvent may be included. In certain embodiments of the present formulations, useful solvents include: In particular, water-soluble polar organic solvents such as methanol, ethanol, propatool, Including butanol and carbonyl-containing solvents such as acetone, butanone, etc., among others be done. Additional solvents include ethers and amines such as diethyl or dipropylene. and trimethylamine or triethylamine. Triethyl Amines and triethylamine can also be added as bases.

Solvents added to the formulation can increase the solubility of certain components. liquid distribution When compounds are contemplated, organic solvents are often added, and no organic solvent is added. In other words, the composition consists of dissolution of certain less polar components that separate into more than one phase. It is often recommended to promote degree. Addition of organic solvent is uniform and homogeneous. One phase is formed.

Emollients may be included in particular in lotions to form a uniform, homogeneous phase; and other advantageous properties. Particularly preferred for use in the formulations of the invention Emollients such as PPG can also be added to the formulations of the present invention due to its emulsifying properties. 15-sterol ether.

Emulsifiers or surfactants, i.e. those mentioned above, stabilize the composition and have a malodor. Cations added in some embodiments to reduce by-product formation Surfactants other than natural or nonionic surfactants increase the properties of the formulation. , to promote solubility of proteins and other ingredients, and to promote phase stability of the formulation. It is often added to embodiments of the invention for this purpose. Such substances may also be used as cleaning agents. impart similar properties to the formulation. Suitable surfactants or emulsifiers include non-ionic, anionic Can be onic or amphoteric. Of course, those skilled in the art will appreciate that combinations of surfactants can be used. When used, the type and amount of surfactant should be adjusted to maintain emulsion stability. You will realize that you need to get things sorted out. Non-ionic emulsifying compositions include e.g. For example, lower alkylene oxide condensation products of hydrophobic compounds, e.g. Oxides with higher fatty acids, higher fatty alcohols or alkylated aromatic hydrocarbons condensation products, and high molecular weight polypropylene glycols.

Preferred nonionic emulsifying compositions include polyoxyethylene isohexadecyl ether. Tel, for example Alasolve (person+la+olve) 200 [: Trademark name, IC Polyoxyethylene, obtained from I. (Wilmington, Praue State, USA) Renlauryl ethers, such as Brii 35 (trade name, from ICI) Polyoxyethylene stearyl ether, such as Brij 72 (Trademark) ) and Brisif 8 (obtained from ICI), and polyoxypropylene stearyl ethers, such as PPG-15 stearyl ether [Arxmo 1) Polyoxyethylene ethers containing E, I from CI) are included.

Other typical emulsifiers include ethoxylated lanolin, such as lanogel (La nogel) 41 [Ame+chol Inc., - Edison, NE]. Typical anionic surfactant include sulfate esters of polyhydric alcohols, such as lauryl sulfate, cetyl sulfate, etc. Higher fatty alcohol sulfates derived from coconut oil, such as 2,3-dihydroxy Hydroxysulfonated polymers such as higher fatty acid esters of cypropane sulfonic acid Fatty acid esters, higher fatty acid esters of low molecular weight alkylol sulfonic acids, e.g. For example, oleic acid ester of isethionic acid (i+ejhionic acid) , for example, sulfated higher fatty acid alkylolamides such as ethanolamide sulfate. higher fatty acid amides of amine alkylsulfonic acids, such as laurine, especially taurine. Includes phosphoric acid amides, and aromatic-containing anionic synthetic surfactants. Typical Amphoteric surfactants include alkyl groups, especially fatty acids such as coconut oil fatty acid mixtures. Contains salts of N-alkyl compounds of β-aminopropionic acid derived from fatty acids. Ru.

In certain compositions it is possible to promote homogeneity and prevent foaming from the action of surfactants. Preference is given to adding foaming agents.

Preferred antifoam agents for use in embodiments of the invention include, for example, dimethicone [(Dims+hicone), trade name, Dow Chemical Corporation (Mishi (obtained from Midland, Gan State).

Added weight or more active feel to the formulation or, in some cases, additional film-forming properties Thickening or gelling agents may be added to impart to the compositions of the invention. Suitable thickening The agent includes, for example, PVP K2O [GAF Cha+1oHe] Polyvinylpyrrolidone, polyacrylate, such as , NC Carbomers (exrbomez), for example, carbapol (Ca+bxpo l) 940 [B, F, Gutdrich (Good+1ch), Ohio, Ku Carboxyvinyl polymers such as Leebrand, Steare th) 2 (trade name) from ICI], such as polyoxyethylene-2 stearyl ether and polyesters such as Steareth 20 (trade name, from ICI). Oxyethylene-20 stearyl ether, sodium alginate, carragina agar, ethoxylated polyvinyl alcohol, e.g. methylcellulose, Droxymethylcellulose, carboxymethylcellulose, propylcellulose and hydroxypropylcellulose, acacia, tragacanth, guar and quince This includes gums such as lollipops. Intended to be formulated as a gel or lotion Isocetes (1+o+e++lh) 2 and 20 (trademark) Polyoxyethylene isohexadecyl ether (ICI) and Steareth 2 and 20 are preferred for use as thickeners. It is planned to be formulated as a cream. In the illustrated compositions, preferred thickening agents include Steareth 2™ and Steareth Ares 20™ and carbomer polymers, such as Carbapol 94o (commercial ) is included.

Preservatives are added to prevent the growth of microorganisms in the presence of protein nutritional substances. Ru. Typical preservatives include benzoic acid analogs, including sodium benzoate, among others. be caught. Other preservatives include propyl and methylparaben, Taushi/I/[ (Doucil), trade name, Dow Chemical Corporation, Mississippi State, Midland] and polmaldehyde solutions. Particularly preferred preservatives are , Gerzaben II (trade name, Saraton Laboratories) (New Jersey, New York).

To disinfect the wound and surrounding tissue and to provide antimicrobial protection. Other substances may also be added to embodiments of the invention intended to treat wounds for . Preferred materials for this use include topical disinfectants such as benzalcohol, among others. Fungicides like nium chloride, cetrimide, chloramine, chlorhexidine is included.

Antimicrobial agents that can be used in the present invention include, among others, neomycin, bacitracin, spectra Tinomycin, sulfa drug-containing preparations, polymyxin and griseofulvin, Nphotericin, Chlorantoin, Clotrimazole, Dimetizole, Miconazo Antifungal agents include antifungal agents such as antifungal agents and nyscutin.

Colorants and fragrances may also be added to enhance the properties of the formulation.

In addition to many cosmetic and therapeutic uses, the compositions of the invention can be used to treat bed layers. can be used. Preferred compositions for treating bed layers include a pharmaceutically effective amount of benzene. In combination with zoyl peroxide, tetracycline and other layer agents, the present invention The composition includes a light composition. The composition of the invention can be used to treat pockmarks in people who have not had a bed coat for many years. It can also be used to heal the back of the bed. The compositions of the invention may also be used with age or Improves wrinkles caused by overexposure to the sun and promotes hair and nail growth. , used to prevent hair loss.

Compositions of the invention may also be used to treat dandruff.

Particularly preferred compositions for treating dandruff include an effective amount of a conventional dandruff agent, such as ginseng. including the compositions of the present invention in combination with cupirithion.

Compositions useful in the invention can be processed as liquids, creams, gels or lotions. The composition is rubbed onto the keratin tissue to be treated. In general, its composition The material is used in an effective amount to form a thin film in the area to be treated.

After application, the compound is allowed to dry. In some cases, drying is done by heat or air circulation. will be promoted. Although not preferred when the composition is used to treat wounds, After drying, the formulation may be washed off. When treating dandruff or seborrhea, before drying The composition can be washed off.

The method of the invention comprises treating an area of keratinous tissue with any one of the above compositions. Including attaching to. Depending on the type of skin condition to be treated or hair, skin or nails Depending on the desired cosmetic effect, once or more a day and to improve symptoms. Apply the therapeutic composition to the affected area as many times as necessary. Generally, treatment is performed 1 to 4 times a day. Apply the therapeutic composition to the affected area. Depending on the use, indication, and severity of symptoms, especially in the beauty field. In , fewer than one application per day is made. For example, dandruff, seborrhea and For non-wound skin conditions, shampooing may be once or twice a week. Simply apply the formulation after or during shampooing. During the treatment period, treat Depending on the condition and the response of symptoms to treatment. Therefore, conventional treatments are not effective. When treating a more severe chronic condition, the duration of treatment may be longer than when treating a less severe condition. It will be longer than before.

Many methods can be used to make the compositions of the invention. However, its composition A preferred method of producing is to first activate a protein containing sufficient cysteine groups. and then one or more reactive zinc salts, cationic polymers, or cationic the activated protein in the presence of a surfactant selected from nonionic and nonionic surfactants. and methods of stabilizing and substantially reducing the production of malodorous by-products.

The method, as described herein, includes a p H activates proteins containing cysteine groups and reduces some thiol groups. i.e. the thiol is a mercap rather than a dithiol (cystine group). It involves producing proteins that exist as cysteine groups. activation engineering After treatment, an effective amount of one or more reactive zinc salts, a cationic polymer, and a cationic A surfactant selected from ionic and nonionic surfactants is used as a reducing agent and activated. Combine with proteins and other ingredients. For reactive zinc salts, some zinc salts, e.g. For example, they are often completely soluble in water or other carriers used in formulating the compositions of the invention. 2nO (the water solubility of 2nO is, for example, 0.00016 g/1oO cc) in water or other carrier than in the absence of protein and reducing agent. It was unexpected to find that the amount dissolved.

Of course, simply adding the ingredients to the protein, regardless of timing (+iming) or activation of the protein ingredient. It is also possible to produce the compositions of the invention by mixing with white matter. this method proteins contain insufficient cysteine groups, i.e., they are shared with the keratin matrix. There are fewer cysteine groups to attach to, resulting in a covalent bond to the protein substrate. When it is a film-forming protein, such as gelatin or collagen, that cannot be are useful for producing the compositions of the present invention. However, such film-forming proteins Even when white matter is used, in some formulations such compositions are reactive zinc that can be formulated and dissolved in the composition at a pH greater than about 90 in the presence of an agent; It is advantageous to accelerate the amount of salt.

Without being bound by theory, the unexpected The therapeutic activity is the combination of pharmaceutical effects retained by the use of the stabilized products of the present invention. This is thought to be the result of a combination of Biological sources of protein and the medium in which it is contained Given the reaction characteristics of the body, the potential for the formation of biologically reactive products can be considered. considered.

These biological products are responsible for humidification of the area of action by hydrated proteins, thin film formation, and resulting from cell-skeletal interactions and mediating the coagulation process, creating a “natural covering cloth” effect. covalent disulfide bond formation with the keratin matrix, endogenous mediators of skin function (e.g. release of fibronectin, kinins and prostanoids), receptor degeneration and vasodilation Contribute to the biological effect of many possible mechanisms of action including. The composition of the present invention is For example, if the title of the invention is compositions z++d11ejhod+ Ior Treuin g 5kin Conditions snd Promoting Wound ing J, U.S. Patent Application No. 319.402, filed March 3, 1989. No. and rs+ortge 5Hble Compositionsxnd Me thods jar Treating K! ruinous Ti5sueJ No. 319,14, filed March 3, 1989, entitled No. 7 (the relevant parts of which are incorporated herein by reference). This is a surprising result, as it retains substantially the same activity as the same composition.

The following examples are intended to illustrate the invention and do not limit the scope of the invention of this application. It should not be construed as defining

Example 1 Phase component weight% A, l Deionized water 61.90 B, l Propylene glycol 0.15B, 2 LANOGEL ) 41 0.158J BRIJ 35 0.41 B, 4 PVP- to 3Q (25% solution) 0.70C, l Glycerin 0 ．． 50 C,2 Citric acid (5,88% solution) 014C3 Hydrogen peroxide (3% solution) 1.6 1C,4 acetone 0.41 C,5 isopropanol (99% solution) 1.20C,6 Keras QL) 5.81D, l GERMABEN II 2.93 E, 1 Ammonium thioglycolate 10.34 (60% solution) (Pre-adjusted to pH=9 with NII3) E, 2 Deionized water 8.55 Ej Keraturu 2.95 F, l HAMPENE too (EDTA) 0.58G, l Zinc oxide 1.47 11.2 Zinc sulfocarbonate 0.29 Total percentage 100.00 In general, all metals (machinery, containers or other items) are completely ``pickled,'' i.e., unprocessed. Treated with industrial grade nitric acid (1N) to avoid the effect of metal oxides on the reducing agent during formulation. Ru.

1. Heat Phase A to 100°F.

2. Combine Phase B ingredients separately and heat separately at about 125°F until 8.3 melts. . Mix thoroughly and then add to Phase A for 10 minutes at 100°.

3. Premix the ingredients in Phase C in the order listed with continuous mixing. phase Add C to phases A and B still at 100° and mix for 10 minutes.

4. Add phase to phase ABC with mixing and mix for an additional 10 minutes. That bag The water will become cloudy at this point, but this is normal.

5. Combine ingredients in Phase E in the order listed and mix for IO minutes. This process is , is for activating Keraturu. Add Phase E to Phase ABCD while mixing. Add and continue mixing for 10 minutes. The batch will turn into a clear liquid.

6. While continuing to mix, add Phase F to the batch and mix for 10 minutes.

7. Mix at high speed and swirl (if possible). Slowly phase G , followed by Phase H directly to the batch in a vortex. These powders are completely dissolved Mix until combined. Depending on the efficiency of the mixing process, it takes up to 30 minutes Example 2 A, I Concentrated stock solution from Example 1 34.11A, 2 Deionized water 60. 33 B, l ARLASOLVE 200 (trade name) 400C1 sa Rufidon (SL'RFIDO'1E) LP-100 (trade name) 0.66 C92 cents (SCENT) 0.90 total percentage 100.00 process 1. Combine Phase A ingredients, then add Phase B to a separate container and heat to 145-150°F. Heat and keep at that temperature.

2. Combine 01 and C2, mix well and let stand for 5 minutes before adding phase B; Mix mechanically for an additional 5 minutes.

3. While mixing Phase A, add combined Phases B and C to Phase A. The result is approximately It is a clear liquid with a pH of 8.1.

Example 3 A, l Alamol (A+lamol) E (trade name) 1.36.2 Buri B+ii 72 (trade name) 5.21.3 Mineral oil 70 11.60 ．． 4 Propylparaben 0.18 B,! Purified water 77.4 ．． 2 Disodium (Di+odiuz) E D T A If, 103 Di Methicone (trade name) 11.09.4 Methylpa Laben 0.41 5 Propyl glycol 1.36 C,1 Dowicil 200 (trade name) 0.05.2 Precision Water production 0.50 D, l Formaldehyde 37% [1,2E, I Germab en) II (trade name) 0.231, heating phase A components to 70-75°C, Mix until homogeneous.

2. Add water to the main strainer and start heating to 70-75℃.

3. Add the remainder of Phase B ingredients and mix to dissolve the solids.

4. Add phase A to phase B with mixing at 70-75°C. Mix well 35-40 Cool to ℃.

5. Premix Phase C and add to batch when solution becomes clear. D and E Combine the phases into one at the same time and mix well Example 4 A.1 Deionized water 56.15 E,! CARBOPOL 940 (trade name) 1.60C I GERMABEN II (trade name) 04゜D,! Example Lotion from 3 8.70E, 1 Triethanolamine (99% solution) 1 ．． 43F, 1 Concentrated stock solution from Example 1 30.2061 Sulfidone ( SURFIDONE) LP-1000,65 total percentage 100.0 0 Two pieces 1. Place phase A in a high-speed mixer, create a swirl, and sprinkle phase B into the swirl. , mix until thoroughly blended.

2. Add Phase C to Phase AB without mixing and mix until homogeneous.

3. Pre-mix the ingredients. Add phase to phase ABC and mix until completely homogeneous. do.

4. Add Phase E to Phase ABCD. This turns the batch into a gel. completely Mix until homogeneous.

5. Premix Phase F and add to another container sufficient to hold Phases F and G.

6. Premix Phase G, mix well and let stand for 5 minutes. Add phase G to phase F and machine Mix for 1 G minute. Continue mixing and add phase FG to phase ABCD while mixing. Ru.

Continue mixing until smooth and homogeneous.

7, the final pH is approximately 5.85.

Example 5 ^, 1 Concentrated stock solution from Example 1 91.42B, I 7-Lasolve (AR LASOLVE) 200 (Trade name) 5.9C, I Sulfide: / (SU RFIDONE) LP-100 (trade name) 178 Total percentage 100. 00 1. After preparing Phase A, place Phase B in a separate container and heat to 145-150'F. and hold at that temperature.

2. Combine C,l and C,2, mix well, leave for 5 minutes, then add phase B. Add and mix mechanically for an additional 5 minutes.

3. While mixing Phase A, add combined Phases B and C to Phase A. It makes about It becomes a clear liquid with a pH of 8.1.

Example 6 A, 1 Alamol (trade name) 2.33.2 Bri Broi? 2 (trade name) 8.93.3 Bridge 78 (trade name) 2 ．． 25.4 Mineral oil 7G 19.89 ．． 5 Propylparaben 0.31 B.1 Purified water 62.15 ．． 2 Disodium EDTA 0.16 3 Dimethicone (trade name) 0.16 ．． 4 Methylparaben 0.70 Ethylparaben 2.33 C, I Germaben II (trade name) 0.79 steps 1. Add component B to the main mixing pot and heat to 8G-85℃ while mixing. .

Mix with

3. At 80-85℃, mix the mixed A component with the mixed B component while thoroughly mixing. Added.

°4. Cool the mixture of A and B to 50-55°C. Add germaben (C) Blend very well. Continue cooling to 30°C and use at this temperature.

Example 7 A.1 Deionized water 56.30 B, 1 CARBOPOL 940 (trade name) 238C, l GERMABEN IF (trade name) 0.590.1 Real Lotion from Example 6 8.90E, 1 triethanolamine (99% solution) 025F, I Concentrated stock solution from Example 1 30.20G, I Sulf SURFIDONE LP-100 (trade name) 0.50 Total percentage 100.00 process 1. Place phase A in a high-speed mixer, create a swirl, and sprinkle phase B into the swirl. , mix until completely blended.

2. Add Phase C to Phase AB without mixing and mix until homogeneous.

3. Pre-mix the ingredients. Add phase to phase ABC and mix until completely homogeneous. do.

4. Add Phase E to Phase ABCD. This turns the batch into a gel. completely homogeneous Mix until .

5. Premix Phase F and add to another container sufficient to hold Phases F and G.

6. Premix Phase G, mix well and let stand for 5 minutes. Add Phase G to Phase F for 10 minutes Mix mechanically for a while. Continue mixing and add phase FG to phase ABCD while mixing. . Continue mixing until smooth and homogeneous.

7, the final pH is approximately 5.4.

Example 8 A, l Concentrated stock solution from Example 1 34.11A, 2 Deionized water 60. 75 B, 1 7- ARLASOLVE 200 (trade name) 4. OQC, l Sulfidone (SURFIDONEI LP-100 (trade name) 0.66 C, 2 cents (SCE!IT) 0.48 total percentage 100.00 J 1. Combine the ingredients of phase A, then add phase B to another container, +45-150' Heat to F and maintain at that temperature.

2. Combine C,1 and C,2, mix well, leave for 5 minutes, then add phase B. Add and mechanically mix for an additional 5 minutes.

3. Add combined Phases B and C to Phase A while mixing Phase A. Thereby, approx. It becomes a clear liquid with a pH of 8.1.

Example 9 A1 Deionized water 5635 B, 1 force/l, l CARBOPOL 940 (trade name) 16°C , ]'f Lua Pen (GERMABEN) II (trade name) o49D1 Lotion from Example 3 8.70E, lh Reethanolamine (99% soluble) Liquid) 143F, l Concentrated stock solution from Example 1 30.20G, l f Luffy G:z (SURFIDONE) LP-100 (trade name) 045G, 2 cents (SCE!i-dou) 0.87 Total percentage 100.00 1. Put phase A into a high-speed mixer, create a swirl, and pour phase B into the swirl. , mix until completely blended.

2. While still mixing, add Phase C to Phase A and B and mix until homogeneous.

3. Pre-mix the ingredients. Add phase to phase ABC and mix until completely homogeneous. do.

4. Add Phase E to Phase ABCD. This turns the batch into a gel. completely homogeneous Mix until .

5. Premix Phase F and add to another container sufficient to hold Phases F and G.

6. Premix Phase G, mix well and let stand for 5 minutes. Add phase G to phase F and add 10 Mix mechanically for a minute. Continue mixing and add phase FG to phase ABCD while mixing. Ru.

Continue mixing until smooth and homogeneous.

7, the final pH is approximately 585.

Example 10-16 Formulations containing cationic polymers 05.1.2.3.4.5 and 6% by weight of cationic polymers were added to the concentrated liquid of Example 11. Add Rimmer JR-400.

All samples were found to be active. Compatible with dose across the range tested There was a reduction in the odor of malodorous thiols or sulfides. 5 and 6 % JR-400 is very viscous and undesirable as a therapeutic liquid. It didn't feel good. Liquids containing 4% JR-400 are highly desirable in terms of viscosity. It had the perfect fragrance profile.

Example +7-18 0.45% sulfitone (+u+jido) in concentrated stock solution (Example 1) nc) LP-100 was added until the mixture was completely homogeneous. This results in , produced a composition in which further odor reduction occurred, but retained efficacy (similar to (see Example 2). Add JR-400 to this zinc/sulfitone mixture. It was added up to about 4% by weight. Furthermore, the composition has reduced odor, making it useful and effective. A composition having the following properties was produced. The effect of excessive surfactants can be reduced by thinner and more This appeared as inhomogeneity in the formulation, with thick regions observed. This composition The results showed that the odor was reduced and the composition was useful.

Treatment example Example 19-23 Horses with bilateral subsaddle deviations that made riding impossible were treated with the formulation from Example 4. Treated using. Within a day, the sores were gone and I was able to ride a horse. 3 days Within 2.5 weeks, new hair growth is visible and the affected area is distinguishable from the rest of the skin. I couldn't do it.

A 33-year-old woman used the formulation from Example 7 on her fingernails for two weeks to determine the hardness and growth rate. A dramatic increase in was observed.

8 of the above-mentioned women who are prone to bulges and have multiple bulges on each finger. A year old daughter was treated with the formulation from Example 7. Uncomfortable swelling within 2 days disappeared. There was a significant reduction in sagging that was observable within one week. 2 weeks Only one reversal was observed within the interval. The mother has only one daughter I couldn't remember a time when all I had was Muke.

A boxer-sized cat that had been specifically licking its front paws from birth until 4 years ago was transferred to the patient from Example 10. treated with a compound. Antibiotics, steroid hormones, antihistamines and Other foul tasting compositions (foul+asjing compost) All previous treatments with ion) were unsuccessful. 30 days after first administration The licking behavior disappeared within a day. When treated with this formulation, licking behavior is observed. In fact, it's gone.

When it occurs again, repeated administration effectively stops licking within 5 minutes. .

A 15-month-old infant with moderately severe diaper rash was treated with the drug from Example 7. The formulation was used once - overnight for treatment. In the morning, about 85% of the rash was gone. destination Both children have other children who have experienced similar episodes of diaper sores. Parents were surprised by the reaction.

The present invention has been described so as to be understood and practiced by those skilled in the art, and the preferred embodiments have been described to enable those skilled in the art to understand and practice the invention. The embodiment has been fully identified. However, although much is described in the examples below, this book It is understood that it should not be considered as limiting the invention.

Example 24 odor reduction reactive zinc salts, cationic polymers or cationic or nonionic surfactants. Formulas that do not contain this product are forced to emit a heavy, boring fragrance. It gave off a foul odor. The fragrance used to cover the bad odor is heavily Not ideal due to the strong aroma and need to use high concentrations. of fragrance-free compositions Although an improvement, it is not very comfortable and exhibits some instability.

reactive zinc salts, cationic polymers or cationic or nonionic surfactants. The composition used needs only half the fragrance concentration mentioned above, and has a lighter, saba so that the aromatic scent can be used to enhance the odor of the formulation. The odor of the formulation was reduced in minutes. Significant comfort with smells and increased compliance It was a combination.

Example 25 Reducing container pucke-in High-density or low-density polyethylene bottles The previous destabilizing formulation partially disintegrates the bottle when placed in the bottle. This is new resulting from a chemical reaction between the compound after it has been made and the gas in the container. it is conceivable that. During the reaction with the composition in the formulation, the gas in the container is removed and The gas reduces and causes wrinkles. reactive zinc salts, cationic polymers or The resulting stabilization using cationic or nonionic surfactants This results in a cessation of interaction between the object and the gas in the bottle, and no wrinkles occur.

Example 26 Reduced precipitation Certain destabilizing formulations, particularly those containing high concentrations of proteins and thioglycolates Precipitation occurs over a long period of time.

This precipitate contains zinc salts, cationic polymers and/or cationic or nonionic No precipitation occurs when surfactants are added to the formulation as described above.

international search report

Claims (1)

[Claims] 1. a) about 0.01 to about 25.0% by weight of film-forming protein, b) about 0.1 to about 25.0% by weight about 15% by weight of a compatible reducing agent; c) at least about 0.05% by weight of a reactive zinc salt; and d) water, acids, bases, buffers. , emulsifiers, thickeners, solvents, preservatives, chelating agents, film-forming polymers, oxidizing agents, at least one component selected from the group consisting of colorants, fragrances and mixtures thereof; minutes A composition for treating mammalian keratin tissue, comprising: 2 Sufficient silicon for the thin film-forming protein component to covalently bond to the keratin tissue. The composition according to claim 1, which is a protein containing a stain residue. 3 The reactive zinc salt is zinc oxide, zinc sulfocarbonate (zinc sulfocarbonate), according to claim 2, selected from the group consisting of Compositions as described. 4. The composition according to claim 2, wherein the protein is keratin. 5 The compatible reducing agent is dithiothreitol, trithiohexitol, glutamate. Thione, cysteine, mercaptoethanol, thioglycerol, mercaptococo Thiolactic acid succinate, thioglycolic acid, their pharmaceutically acceptable salts and the like 1. A thiol-containing material comprising a material selected from the group consisting of a mixture of The composition described in . 6. The method according to claim 5, wherein the compatible reducing agent is thioglycolic acid or a salt thereof. Composition. 7. the oxidizing agent is in an amount ranging from about 0.01 to about 1.5% by weight of the composition; selected from the group consisting of sodium perborate, sodium bromate and hydrogen peroxide; A composition according to claim 2. 8. The composition of claim 1, further comprising an effective amount of a cationic polymer. 9 The cationic polymer is about 0.01 to about 20% by weight of the composition. 9. The composition of claim 8, wherein the polymer is a quaternary ammonium-containing polymer. 10. Claim 9, wherein the polymer is a quaternary nitrogen-containing cellulose ether. Composition of. 11. The film-forming protein component has sufficient content to covalently bond to the keratin tissue. The composition according to claim 8, which is a protein containing cysteine residues. 12. The composition according to claim 11, wherein the protein is keratin. 13 The compatible reducing agent is dithiothreitol, trithiohexitol, glucose Tathion, cysteine, mercaptoethanol, thioglycerol, mercapto Succinic thiolactic acid, thioglycolic acid, their pharmaceutically acceptable salts and the like The claim is a thiol-containing substance comprising a substance selected from the group consisting of a mixture of 12. The composition according to 11. 14 The oxidizing agent is hydrogen peroxide, and the oxidizing agent is about 0.01 to about 1.5 weight of the composition. 14. The composition of claim 13, consisting of %. 15 About 0.05 to about 15% by weight of cationic and nonionic surfactants According to any one of claims 1 to 9, further comprising a surfactant selected from Composition of. 16 The surfactant binds n-octyl, dodecyl and non-substituted with a hydrophobic group selected from the group consisting of 16. The composition of claim 15, which is an ionic pyrrolidone-containing surfactant. 17. The thin film-forming protein component has sufficient content to covalently bond to the keratin tissue. The composition according to claim 15, which is a protein containing cysteine residues. 18 Reactive zinc salts are prepared from zinc oxide and zinc sulfophosphate and mixtures thereof. 18. The composition of claim 17, wherein the composition is selected from the group consisting of: 19. The composition according to claim 18, wherein the protein is keratin. 20 The compatible reducing agent is dithiothreitol, trithiohexitol, glucose Tathion, cysteine, mercaptoethanol, thioglycerol, mercapto Succinic thiolactic acid, thioglycolic acid, their pharmaceutically acceptable salts and the like The claim is a thiol-containing substance comprising a substance selected from the group consisting of a mixture of 17. The composition according to 17. 21. The method according to claim 20, wherein the compatible reducing agent is thioglycolic acid or a salt thereof. composition. 22. The composition of claim 15, further comprising a chelating agent. 23. The chelating agent is equal to about 0.05 to about 2.0% by weight of the composition. 23. The composition of claim 22, comprising: 24. Claim 2, wherein the oxidizing agent comprises from about 0.01 to about 1.5% by weight of the composition. 2. The composition according to 2. 25 The protein is keratin, the reducing agent is ammonium thioglycolate, The zinc salt is zinc oxide and zinc sulfocarbonate, and the surfactant is pyrrolidone. A pyrrolidone-containing surfactant having an n-octyl group substituted on the nitrogen group. and the composition further comprises hydrogen peroxide and ethylenediaminetetraacetic acid. The composition according to item 15. 26 a) about 0.01 to about 25.0% by weight of a film-forming protein; b) about 0.1 to about 25.0% by weight of a film-forming protein; up to about 15% by weight of a compatible reducing agent; c) to substantially reduce the production of malodorous byproducts; an effective amount of a cationic polymer and d) Water, acids, bases, buffers, emulsifiers, thickeners, solvents, preservatives, chelating agents, thinners A small amount selected from film-forming polymers, colorants, oxidizing agents, fragrances and mixtures thereof. At least one ingredient A composition for treating mammalian keratin tissue, comprising: 27 The thin film-forming component contains enough cysteine residues to covalently bond to the tissue. 27. The composition according to claim 26, which is a protein comprising. 28 The cationic polymer comprises at least about 0.01% by weight of the composition. 27. The composition of claim 26, which is a quaternary ammonium-containing polymer. 29. The composition according to claim 27, wherein the protein is keratin. 30 The compatible reducing agent is dithiothreitol, trithiohexitol, glucose. Tathion, cysteine, mercaptoethanol, thioglycerol, mercapto Succinic acid, thiolactic acid, thioglycolic acid, their pharmaceutically acceptable salts and The claim is a thiol-containing substance containing a substance selected from the group consisting of mixtures thereof. The composition according to item 27. 31 About 0.05 to about 15% by weight of cationic and nonionic surfactants 31. The composition of claim 30, further comprising a surfactant selected from the group consisting of: 32 The surfactant binds n-octyl, dodecyl and and substituted with a hydrophobic group selected from the group consisting of coconut and tallow alkyl groups. 32. The composition of claim 31, which is a nonionic pyrrolidone-containing surfactant. 33. The composition according to claim 32, wherein the film-forming protein component is keratin. 34. The compatible reducing agent may be dithiothreitol, trithiohexitol, or glucose. Tathion, cysteine, mercaptoethanol, thioglycerol, mercapto Succinic acid, thiolactic acid, thioglycolic acid, their pharmaceutically acceptable salts and The claim is a thiol-containing substance containing a substance selected from the group consisting of mixtures thereof. The composition according to item 33. 35 a) about 0.01 to about 25.0% by weight of a film-forming protein; b) about 0.1 to about 25.0% by weight of a film-forming protein; up to about 15% by weight of a compatible reducing agent; c) substantially reducing the production of malodorous byproducts; an amount of a cationic and nonionic surfactant selected from the group consisting of cationic and nonionic surfactants; surfactants and d) water, acids, bases, buffers, emulsifiers, thickeners, solvents, preservatives, selected from the group consisting of oxidizing agents, film-forming polymers, oxidizing agents, coloring agents, and fragrance agents. at least one ingredient A composition for treating mammalian keratin tissue, comprising: 36. Claim 36, wherein the surfactant comprises from about 0.05 to about 15% by weight of said composition. 35. The composition according to 35. 37 The surfactant has n-octyl, dodecyl, or and substituted with a hydrophobic group selected from the group consisting of coconut and tallow alkyl groups. 36. The composition of claim 35, wherein the composition is a nonionic pyrrolidone-containing surfactant. 38. The composition according to claim 35, wherein the film-forming protein component is keratin. 39 The compatible reducing agent is dithiothreitol, trithiohexitol, glucose Tathion, cysteine, mercaptoethanol, thioglycerol, mercapto Succinic acid, thiolactic acid, thioglycolic acid, their pharmaceutically acceptable salts and The claim is a thiol-containing substance containing a substance selected from the group consisting of mixtures thereof. The composition according to item 35. 40. The method according to claim 39, wherein the compatible reducing agent is thioglycolic acid or a salt thereof. composition. 41 The oxidizing agent is composed of sodium perborate, sodium bromate, and hydrogen peroxide. selected from the group consisting of about 0.01 to about 1.5% by weight of said composition. 39. The composition according to 39. 42 The composition according to any one of claims 1 to 41 is attached to keratin tissue. To improve its condition, appearance, strength and promote its strength by contacting A method of treating normal and abnormal keratin tissue. 43. Any one of claims 1 to 41 on the area of the skin where the effect is brought about. Wounds, abrasions, pressure sores, teeth, including applying a composition containing the composition described in chyme, oral sores and sores, corneal ulcers and abrasions, seborrhea, dryness Rash, acne, acne scar length, itching, hard skin, corns, burns, various skin eruptions, non-specific Dermatitis, eczematous dermatitis, wrinkles, inverted skin, chronic dermatitis, equine bulge granuloma, decubitus ulcer For treating keratinous tissue conditions in mammals, including canine skin granulomas. Law. 44 a) from about 0.01 to about 25.0% cysteine by weight of the composition in solution; containing proteins in water or a suitable solvent at a pH of at least about 9.0. Exposure to about 0.1 to about 15% by weight of the composition of a thiol-containing reducing agent. and producing an activated protein mixture; and b) Reactive zinc salts, cationic polymers and cationic and nonionic surface activities a surfactant selected from the group consisting of at least about 0.05% by weight of said composition; dissolving in the activated protein mixture at least one component selected from A method of producing a composition for treating keratinous tissue, comprising: 45 After the soaking step a, add the activated protein to about 0.01 to about 0.01% of the final composition. 45. The method of claim 44, wherein the oxidizing agent is immersed in an amount of about 1.5% by weight. 46 After the dissolution step b, the activated protein is added to about 0.01 to about 0.01% of the final composition. 45. The method of claim 44, wherein the oxidizing agent is immersed in an amount of about 1.5% by weight. 47 Before the dissolution step b, the activated protein mixture is first treated with water, an acid, and a base. , buffering agents, emulsifiers, thickeners, solvents, preservatives, chelating agents, film-forming polymers, 45. Mixed with at least one component selected from colorants and fragrances. How to put it on. 48 a) about 0.01 to about 25.0% by weight of a film-forming protein; b) about 0.1 to about 25.0% by weight of a film-forming protein; up to about 15% by weight of a compatible reducing agent; c) water, acids, bases, buffers, emulsifiers, thickeners; Solvents, preservatives, chelating agents, film-forming polymers, colorants, oxidizing agents, fragrances and further comprising at least one component selected from the group consisting of mixtures thereof; remainder of the composition Used to treat the effects of aging skin, including wrinkles and hair growth, nails Compositions for use in promoting hair growth and stabilizing hair loss . 49. The oxidizing agent of claim 48, wherein the oxidizing agent comprises from about 0.01 to about 1.5% by weight. composition. 50. The composition of claim 165, wherein the oxidizing agent is hydrogen peroxide. 51. The composition according to claim 63, wherein the film-forming protein is keratin. 52 Claim wherein the reducing agent is thioglycolic acid or a salt of thioglycolic acid. 66. The composition according to 66. 53. The reducing agent is at least about 0.5 to about 10% by weight of the composition. 68. The composition of claim 67. 54. The composition according to any one of claims 1 to 41 can be used to reduce wrinkles and improve hair Apply to the target skin or scalp to reduce hair loss and promote hair growth. Treats the effects of aging on mammalian skin, including wrinkles, and improves hair growth and nail development. A method of cosmetic treatment that promotes length and stabilizes hair loss.